- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01626339
Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).
Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mohammadreza Peyman, MD
- Phone Number: 1 0060173387260
- Email: drmpeyman@yahoo.com
Study Contact Backup
- Name: Visvaraja Subrayan, Prof
- Email: d.visva@hotmail.com
Study Locations
-
-
-
Kuala Lumpur, Malaysia, 59100
- Recruiting
- University of Malaya Medical Center
-
Contact:
- Mohammadreza Peyman, MD
- Phone Number: 0060173387260
- Email: drmpeyman@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease
Exclusion Criteria:
- History of previous systemic or ocular Anti-VEGF therapy
- History of previous intravitreal injection with any drug
- Intraocular pressure ≥ 22
- Glaucoma
- History or presence of thromboembolic events
- Un-controlled blood pressure
- Blood donation during the previous 3 weeks
- Relevant media opacity of the lens
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPUM/MDU/300/04/03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on Intravitreal Ranibizumab
-
University Hospital, Basel, SwitzerlandCompletedAge-Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
Beijing HospitalCompletedDiabetic Macular EdemaChina
-
Peter A Campochiaro, MDGenentech, Inc.CompletedMacular Edema | Retinal Vein OcclusionUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; Regeneron PharmaceuticalsCompletedDiabetic Macular EdemaUnited States
-
Qena Faculty of medicine, South Valley UniversityRecruitingNon-Ischemic Central Retinal Vein Occlusion With Macular EdemaEgypt
-
Medical University of ViennaCompletedAge-Related Macular Degeneration | Neovascularization, ChoroidalAustria
-
Cairo UniversityTerminatedDiabetic Retinopathy | Diabetic Macular Edema | Vascular Endothelial Growth Factor Overexpression | Macular IschemiaEgypt
-
Instituto de Olhos de GoianiaUnknownAge Related Macular DegenerationBrazil
-
Vista KlinikCompletedAge Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
Pusan National University HospitalNovartisCompletedExudative Age-related Macular DegenerationKorea, Republic of